BD

BioAdaptives IncOOTC BDPT Stock Report

Last reporting period 30 Sep, 2023

Updated 08 Nov, 2024

Last price

Market cap $B

0.001

Micro

Exchange

OOTC - OTC

BDPT Stock Analysis

BD

Uncovered

BioAdaptives Inc is uncovered by Eyestock quantitative analysis.

Rating

To assess the quality of a company's business, we have collected all financial data from the statements and presented them in the form of a single number - the company's rating. Rating value of 100 is the threshold for determining a viable investment.

-43/100

Low score

Market cap $B

0.001

Dividend yield

Shares outstanding

160.49 B

BioAdaptives, Inc. engages in marketing, investigating, and distributing natural plant and algal-based products that improve health and wellness for humans and animals. The company is headquartered in Las Vegas, Nevada. The company went IPO on 2014-07-09. Its products include dietary supplements using natural ingredients and methods of optimizing the availability of nutrients in foods and beverages. Its product line includes PrimiCell, PluriPain, PrimiLung PrimiLive and PrimiSleep. The company markets the Lung Flute and PrimiLungs product in its Lung Armor packaging, emphasizing the anti-viral properties of the nutraceutical and general respiratory health benefits from use of the device. PrimiLive is a nootropic formulation that enhances mental clarity and endurance. PrimiSleep is a natural soporific that aids relaxation and sleep quality. Its animal products include Canine Regen and Equine Regen for dogs and horses, including an Equine All-in-One formulation to trainers, horse owners and boarding stables.

View Section: Eyestock Rating